GlassScriptPhysician profile
Heather Shearin Page
NPI 1477845501
$1,893.54
in general payments reported to CMS, 2019-2025
21 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $486 · 2022: $472 · 2023: $298 · 2024: $342 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $254.56 | 2021-2024 | Bexsero |
| Tris Pharma INC | $232.04 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $204.61 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $152.70 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $146.19 | 2024-2025 | |
| Sanofi Pasteur INC. | $126.64 | 2021-2025 | |
| Neos Therapeutics, LP | $107.69 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Pfizer INC. | $106.42 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $94.19 | 2021-2023 | Jornay Pm |
| Adlon Therapeutics L.P. | $93.15 | 2021 | |
| Merck Sharp & Dohme LLC | $91.57 | 2021-2023 | Vaxneuvance, Gardasil 9, Rotateq |
| Corium, LLC | $89.37 | 2022-2025 | Azstarys |
| Verrica Pharmaceuticals INC. | $37.93 | 2024 | Ycanth |
| Teva Pharmaceuticals USA, INC. | $27.79 | 2021 | |
| Azurity Pharmaceuticals, INC. | $25.15 | 2025 | Alvesco |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $20.20 | 2022 | |
| Organon LLC | $19.32 | 2025 | |
| Genentech USA, INC. | $17.71 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.54 | 2023 | Lyvispah |
| Astrazeneca Pharmaceuticals LP | $14.94 | 2024 | Flumist Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $14.83 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.